Loading market dashboard
Theralase Technologies Inc.
TLTFFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage
Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 ("Financial Statements"). Theralase® will be hosting a conference call on June 9 th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026.
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st, 2025 ("Financial Statements"). Theralase® will be hosting a conference call on May 12 th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025.
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of Muscle Invasive Bladder Cancer ("MIBC"). Kaplan–Meier survival analysis from the orthotopic MIBC animal study demonstrated that 100% of the animals treated with X-Ray-activated Rutherrin® exhibited a complete response and remained cancer-free at the end of the study; whereas, animals assigned to the radiation only or untreated control group did not respond as well.
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering") of units ("Units") and a Line Of Credit ("LOC"). On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in the destruction of Muscle Invasive Bladder Cancer ("MIBC"). In the MIBC preclinical models conducted by the Theralase® research team, Rutherrin® demonstrated an ability to significantly enhance the efficacy of radiation therapy in the destruction of MIBC, supporting its potential as an effective drug for this devastating condition.
